Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according ...
This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...
Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...
Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2
In recent years, immune checkpoint therapy headed by programmed death receptor 1 (PD-1) and programmed death receptor-ligand 1 (PD-L1) has been proven to be safe and effective. However, clinical ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed ...
The days of broad approvals for PD-1 inhibitors in stomach and esophageal cancers appear to be numbered. A group of external advisers to the FDA voted 10-2 that the use of PD-1 inhibitors in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback